Royalty Pharma (NASDAQ:RPRX) EVP George Lloyd Sells 132,426 Shares

Royalty Pharma PLC (NASDAQ:RPRX) EVP George Lloyd sold 132,426 shares of Royalty Pharma stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $38.34, for a total value of $5,077,212.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Royalty Pharma Price Performance

Royalty Pharma stock traded up $0.53 during mid-day trading on Friday, reaching $38.92. 3,164,604 shares of the company’s stock traded hands, compared to its average volume of 4,278,617. Royalty Pharma PLC has a 12-month low of $24.05 and a 12-month high of $41.24. The company has a quick ratio of 3.48, a current ratio of 3.48 and a debt-to-equity ratio of 0.89. The stock has a 50 day moving average of $36.99 and a two-hundred day moving average of $35.84. The company has a market cap of $22.47 billion, a price-to-earnings ratio of 29.48, a PEG ratio of 2.04 and a beta of 0.56.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.06. The company had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%. Equities analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Friday, November 14th. Royalty Pharma’s dividend payout ratio is currently 66.67%.

Institutional Trading of Royalty Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its position in Royalty Pharma by 868.1% during the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 790 shares in the last quarter. USA Financial Formulas purchased a new stake in Royalty Pharma in the 2nd quarter worth approximately $32,000. Financial Consulate Inc. acquired a new stake in shares of Royalty Pharma during the 3rd quarter worth approximately $35,000. Summit Securities Group LLC purchased a new position in shares of Royalty Pharma during the 1st quarter valued at approximately $36,000. Finally, WPG Advisers LLC purchased a new position in shares of Royalty Pharma during the 1st quarter valued at approximately $39,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Ratings Changes

RPRX has been the topic of several recent research reports. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. The Goldman Sachs Group began coverage on Royalty Pharma in a research report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price objective on the stock. Morgan Stanley cut their target price on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. TD Cowen lowered shares of Royalty Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday. Finally, Weiss Ratings cut shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Royalty Pharma presently has a consensus rating of “Moderate Buy” and an average target price of $46.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.